alectinib   Click here for help

GtoPdb Ligand ID: 7739

Synonyms: AF802 | Alecensa® | CH5424802
Approved drug PDB Ligand
alectinib is an approved drug (FDA (2015), EMA (2017), Japan (unknown))
Compound class: Synthetic organic
Comment: Alectinib is a second generation ALK inhibitor. It was developed to inhibit the expression of the mutated ALK gene that causes growth of some non-small cell lung cancers, in patients whose cancer has become resistant to the older ALK inhibitor, crizotinib [2,5]. However, additional mutations may develop which confer alecitinib resistance [1]. Cells harbouring these novel mutations are reported to be sensitive to ceritinib and other next-generation ALK tyrosine kinase inhibitors [1]. The identification of the mechanisms by which acquired tumour resistance occurs highlights the importance of being able to use the correct drug for the correct patient to maximise the clinical benefit [4]
The design and synthesis of alectinib (CH5424802) is described in [2].
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: alectinib

2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 3
Topological polar surface area 72.36
Molecular weight 482.27
XLogP 5.37
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES CCc1cc2C(=O)c3c4ccc(cc4[nH]c3C(c2cc1N1CCC(CC1)N1CCOCC1)(C)C)C#N
Isomeric SMILES CCc1cc2C(=O)c3c4ccc(cc4[nH]c3C(c2cc1N1CCC(CC1)N1CCOCC1)(C)C)C#N
InChI InChI=1S/C30H34N4O2/c1-4-20-16-23-24(17-26(20)34-9-7-21(8-10-34)33-11-13-36-14-12-33)30(2,3)29-27(28(23)35)22-6-5-19(18-31)15-25(22)32-29/h5-6,15-17,21,32H,4,7-14H2,1-3H3
Bioactivity Comments
Alecitinib has potent anti-tumour effects in crizotinib resistant cells, in in vivo xenograft models [3].
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
ALK receptor tyrosine kinase Primary target of this compound Hs Inhibitor Inhibition 8.7 pIC50 - 2
pIC50 8.7 (IC50 1.9x10-9 M) [2]
MET proto-oncogene, receptor tyrosine kinase Hs Inhibitor Inhibition <5.3 pIC50 - 2
pIC50 <5.3 (IC50 >5x10-6 M) [2]